

**Supplementary Table 2.** Univariate and multivariate analysis of the correlation between variables and pathologic EPE in unfavorable intermediate risk group

Variable	No EPE (n=41)	EPE (n=53)	Univariate analysis	Multivariate analysis	p-value
			p-value	OR (95% CI)	
Age (yr)	67.1±6.9	67.5±6.2	0.748	-	-
PSA (ng/mL)	8.1±3.6	9.6±4.4	0.065	-	-
PSA density (ng/mL <sup>2</sup> )	0.28±0.14	0.33±0.18	0.119	-	-
Clinical ISUP on prostate needle biopsy			0.507	-	-
GGG1	8 (22.9)	2 (13.3)		-	-
GGG2	27 (77.1)	13 (86.7)		-	-
GGG3	25 (61.0)	36 (67.9)		-	-
Maximum percentage of tumor length in a positive core (%)	56.8±27.1	75.9±18.6	0.000	1.029 (1.006–1.052)	0.012
Total positive core rate (%)	33.5±17.8	48.2±20.9	0.001	22.174 (1.339–367.179)	0.030
Clinical stage			0.084	-	-
T1c	14 (34.1)	7 (13.2)		-	-
T2a	14 (34.1)	17 (32.1)		-	-
T2b	7 (17.1)	17 (32.1)		-	-
T2c	6 (14.6)	12 (22.6)		-	-
Suspicious EPE on mpMRI	7 (17.1)	24 (45.3)	0.004	4.432 (1.406–13.411)	0.011

Values are presented as mean±standard deviation or number (%).

EPE, extraprostatic extension; OR, odds ratio; CI, confidence interval; PSA, prostate-specific antigen; ISUP, International Society of Urological Pathology; GGG, Gleason grade group; mpMRI, multiparametric magnetic resonance imaging.